

Modern Slavery Statement 2024

Respecting Ethical Business Practices



lives.

Our vision

To drive significant impact every day in the lives of our people and those we serve. We're leading with a commitment to excellence and delivering superior performance in new and existing markets.

Acknowledgement of Country and Traditional Owners

At EBOS Group, we represent a collective of companies in Australia, New Zealand and Southeast Asia. We acknowledge the traditional inhabitants and the importance of their connections to the lands and communities in which we work. We offer respect and acknowledgement to lands, waters and communities, and pay our respect to Elders past and present.

LEADERSHIP MESSAGE

At EBOS Group, we are committed to striving for the highest standards of conduct and ethical behaviour in all our business activities. This is reflected and supported by our purpose of advancing opportunities to enrich lives – whether that be with respect to members of our own workforce, a commitment to mitigating or preventing modern slavery risks in our supply chains or supporting the communities we serve. Our goal is to engage with suppliers and service providers that are aligned with our broader corporate values, including a respect for human rights and commitment towards ethical sourcing.

The Board oversees the development and implementation of our Environmental, Social and Governance (ESG) Program, as part of its commitment to sound corporate governance. The ESG Program sets out the actions that the Group will take to ensure that we consistently and sustainably deliver on our responsibilities as a provider of essential products and services across our two segments of Healthcare and Animal Care. This includes a commitment to ethical sourcing as reflected in the Group's Ethical Sourcing Strategy.

As reported in our 2023 Modern Slavery Statement, we commenced the roll out of our strategy in FY23 and this roll-out has continued into FY24.¹ We are pleased to report that there has been some progress in each of our segments during FY24 and we will continue the roll out and embedding of the strategy. As we roll out the strategy we learn from our engagement with suppliers and refine our practices to encourage engagement with our suppliers.

The challenges of engaging with a large supplier base remain, however we are committed to ensure that the strategy is embedded.

We are keenly aware that addressing and mitigating modern slavery risks in supply chains is complex and requires a long-term focus and a commitment to continually reviewing and assessing the effectiveness of the measures put in place. In FY24, considering stakeholder feedback we implemented alternative due diligence measures including a manual questionnaire to supplement our online tools. We will continue to look for opportunities to improve and adapt to ensure that we are working towards implementing measures that are most appropriate for identifying and addressing the complexities of our supply chains.

This Modern Slavery Statement was approved by the Board of EBOS Group Limited on 20 August 2024.



HOW TO READ THIS STATEMENT

This is EBOS' fourth Modern Slavery Statement and has been prepared to address the seven mandatory reporting criteria set out in the *Modern Slavery Act 2018* (Cth).

1. Identify the reporting entity.	Page 5 and Appendix A
2. Describe the reporting entity's structure, operations and supply chain.	Page 5-11
3. Describe the risks of modern slavery practices in the operations and supply chains of the reporting entity and any entities it owns or controls.	Page 12
4. Describe the actions taken by the reporting entity and any entity it owns or controls to assess and address those risks, including due diligence and remediation processes.	Page 13
5. Describe how the reporting entity addresses the effectiveness of those actions.	Page 15
6. Describe the process of consultation with any entities that the reporting entity owns or controls (a joint statement must also describe the consultation with the entity giving the statement).	Page 16
7. Include any other information that the reporting entity, or the entity giving the statement, considers relevant.	Page 5-17

INTRODUCTION AND GOVERNANCE


EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading marketer and distributor of recognised animal care brands.

This is EBOS's Modern Slavery Statement for the reporting period 1 July 2023 to 30 June 2024 (FY24). It outlines the steps that we have taken to identify, manage and mitigate the specific risks of modern slavery in our operations and supply chains.

EBOS Group Limited (NZ Company Number 120844/ ARBN 166 840 973) is publicly listed on the New Zealand and Australian stock exchanges and is the parent company of a number of entities that it controls, and, on whose behalf, this joint Modern Slavery Statement is made (see Appendix A). A reference to EBOS in this Modern Slavery Statement includes those entities. Some of the entities within the Group are not reporting entities for the purposes of the Australian Modern Slavery Act 2018, however, we have chosen to focus on the operations of all Australian and New Zealand entities within the Group.

EBOS operates a number of diverse businesses across the Group under the stewardship of our two main segments: Healthcare and Animal Care. In FY24 our businesses continued to focus on more firmly embedding the Group's formal Ethical Sourcing Strategy into their standard business practices. Whilst there are a number of diverse businesses or business divisions within each segment, the Ethical Sourcing Strategy establishes the common processes in relation to ethical sourcing that each business is expected to embed in their operations. Across the Group, each of our businesses is accountable for managing its modern slavery risks. We fully appreciate that the maturity of modern slavery risk management and reporting will evolve over time as well as across each of our businesses and are committed to working towards ensuring that all our businesses are aligned with the Group's expectations on the management of modern slavery risks.

EBOS reported in its FY22 Modern Slavery Statement that it would engage in a process of assessing and integrating modern slavery measures of the newly acquired LifeHealthcare, Australian Biotechnologies and Transmedic businesses within the broader EBOS Group over the reporting period for FY23. Whilst these businesses were included in the roll-out of the Ethical Sourcing Strategy in FY23, FY24 saw more fulsome implementation for the LifeHealthcare business. We anticipate implementation of the Group's strategy in the Australian Biotechnologies and Transmedic businesses to occur in the near future.



OUR ESG GOVERNANCE STRUCTURE AND APPROACH TO ETHICAL SOURCING

Established governance frameworks guide our business towards impactful execution of EBOS' purpose, vision and sustainability framework. The Board and the Executive Leadership Team are committed to leading the sustainable development of our business and the communities we serve.


The Board of Directors is ultimately responsible for sustainability at EBOS and approves, oversees and monitors EBOS' sustainability framework and strategy, including the ESG Program and climate related risks and opportunities.

The Board monitors the Group's Environmental, Social and Governance (ESG) strategy and performance with a focus on five pillars, around which our ESG Program has been structured. The five pillars are:

- Health and Animal Care Partners;
- Consumers and Patient;
- Community and Environment;
- Our People; and
- Responsible Business.

The Consumers & Patients pillar includes measures related to ethical trading of goods and services, including managing risks regarding modern slavery. Ethical Sourcing is a sub-strategy of this pillar focused on enhancing our structured framework to assist business units with evaluating suppliers on ESG compliance and performance in addition to commercial assessments developed to deliver on our ESG Program. It is within this framework that our risks relating to modern slavery will be monitored as part of our broader ESG Program.

The Chief Executive Officer and his Executive Leadership Team are responsible for the delivery of the ESG Program. The Board has assigned responsibility for monitoring and overseeing our ESG Program to the ESG Steering Committee, comprising senior leaders from key functions across all divisions. The ESG Steering Committee is chaired by the Executive General Manager, Strategic Operations, ESG and Innovation.



In FY23, we introduced our Ethical Souring Strategy with the aim of engaging with suppliers that are aligned to EBOS' corporate values and ESG Program and minimising the risk of modern slavery in our supply chains.

The Ethical Sourcing Strategy sets out the steps for our businesses to implement an effective and appropriate ethical sourcing program having regard to the nature and operation of those businesses. This includes risk assessments of certain suppliers, using online due diligence tools and standard operating procedures, reporting templates and contractual protections.

Focus areas of our Ethical Sourcing Framework



Underpinning the Ethical Sourcing Strategy, EBOS implemented policies and procedures in FY23 which apply to our engagement with suppliers:

- Supplier Code of Conduct: this code sets out EBOS' minimum expectations of suppliers in relation to compliance with laws, ethical behaviour, people and safety, environment, quality, privacy and data protection.
- Ethical Sourcing Policy: this policy describes specific requirements regarding ethical sourcing for example, in relation to no use of child labour, employee payments and anti-discrimination and harassment, workplace conditions and environmental standards.

The Supplier Code of Conduct and the Ethical Sourcing Policy are available on our website in the Corporate Governance section—www.ebosgroup.com.

In FY24 our businesses continued to focus on embedding the strategy into their everyday business practices as well as seeking to foster increased supplier engagement and awareness of the EBOS strategy. In the context of continuous improvement, following consideration of feedback through the implementation process, we included an updated manual questionnaire to supplement our online tools. Contractual provisions were also updated to require compliance with the principles set out in the EBOS Supplier Code of Conduct and to encourage greater supplier engagement with due diligence measures.

More information on the Group's broader approach to sustainability is available in our 2024 Sustainability Report. The policy documents referred to this Modern Slavery Statement and the Sustainability Report are available on the Corporate Governance section of EBOS' website – www.ebosgroup.com.

As a market leading healthcare and animal care company, we know that our stakeholders and the communities we serve rely on us

Our ESG Program sets out the actions we will take to ensure we consistently and sustainably deliver on our responsibilities as a provider of essential network infrastructure, products and services.

OUR BUSINESS, OPERATIONS AND SUPPLY CHAINS

EBOS provides wholesale and distribution services and is an intermediary between suppliers and business users including pharmacies, healthcare institutions, veterinarian clinics, medical clinics and other professional care providers.

In doing so, we deal with many local and international suppliers whose finished products we distribute. We also source ingredients for products we manufacture and third- party manufacturers for some EBOS-owned brands such as in our Masterpet and Endeavour businesses. Except for our pet food manufacturing plant and QPharma manufacturing plant (in Australia) and our Red Seal toothpaste manufacturing site (in New Zealand), the Group does not own the factories where EBOS-owned brands are manufactured but engages third parties to manufacture these products.

The Group's broad portfolio of businesses also includes businesses that provide support to the healthcare and animal care sectors in which it operates.

EBOS's core operations can broadly be categorised as falling into two segments:

- Healthcare: sale of healthcare products (including medicines, over the counter products and medical consumables) in a range of sectors, own bands, retail healthcare, pharmacy services, wholesale activities and businesses that provide support to the healthcare sector such as data businesses and sale and distribution of specialist medical devices and consumables to public and private hospitals, surgeons, medical specialists and clinics; and
- Animal Care: sale of animal care products in a range of sectors, own brands, pet food manufacturing, retail and wholesale activities

The businesses that form part of each segment are set out on the following pages:



HEALTHCARE

COMMUNITY PHARMACY





























HEALTHCARE





























CONTRACT LOGISTICS





ANIMAL CARE
















EBOS's registered office is located in Christchurch, New Zealand. EBOS has approximately 5250 employees, and our businesses and functions operate from 115 locations across Australia, New Zealand, and Southeast Asia.² Whilst we have included reference to the Group's broader operations, our reporting in this Modern Slavery Statement is focused on the strategy in our Australian and New Zealand businesses. We will engage in a process of assessing, with a view to integrating modern slavery measures in our Transmedic business (which operates in Southeast Asia) in the near future.

115 locations across New Zealand, Australia and Southeast Asia



Our employees are engaged either under contract or under awards or collective agreements. Across New Zealand and Australia, we have a number of collective agreements, and we engage proactively with unions.



EBOS, by the nature of its business, sources significant quantities of goods from third party suppliers that it then distributes as a wholesaler or distributor. In FY24, across the Group, we had more than 6,900 suppliers. It also sources a wide range of finished products, ingredients and other materials from third party suppliers for its "own brand" manufacturing and retail businesses.

Our supply chains are extensive and sometimes complex, with a high proportion of our supply chain for our Healthcare segment comprising goods sourced from large global pharmaceutical companies and manufacturers based in regions including Europe, the United States and India and Asia. We also source from

businesses located in Australia and New Zealand. Our "own brand" businesses source goods produced locally (being New Zealand) as well as internationally, including geographic locations such as Europe, India, South Africa and Asia. Our Animal Care segment sources products from China, Taiwan, Thailand and Brazil.

There are also a number of third party suppliers that provide services to EBOS to support its business operations, ranging from IT companies, construction, cleaners to freight carriers.

Overview of our Supply Chain

Medicines

In addition to sourcing from local companies, we source over-the-counter products and medical consumables from local branches of global manufacturers, including large pharmaceutical companies.

Medical devices

We typically act as a distributor of overseas-based manufacturers of medical equipment and consumables.

Own-brand products

We have a strong preference to source ingredients and materials for some of our EBOS-owned products from local manufacturers where relevant. We also source inputs and finished products from overseas suppliers.

RISKS OF MODERN SLAVERY IN OUR OPERATIONS AND SUPPLY CHAINS

Our Operations

EBOS Group has assessed the risk of modern slavery in its operations as low. The Group's main operations are based in Australia and New Zealand which are understood to be low risk countries. Our employees are engaged either under contract or under awards or collective agreements. Across Australia and New Zealand, 33% of employees participate in collective bargaining agreements.

In order to align on core behaviours, Integrity Training through an online learning platform has been implemented to support our workforce to fully understand our Group policies and to uphold all legal and regulatory requirements relevant to their roles.

All corporate employees participate in training on Whistleblowing, Anti-bullying & Anti-harassment, Worker Health & Safety and our Code of Ethics. Selected employees depending on their role, also complete additional training on Modern Slavery. For teams in Operations, Warehousing, Manufacturing and Merchandising short burst courses can be accessed via personal mobile devices covering Whistleblowing, Anti-bullying & Anti-harassment, Worker Health & Safety and Privacy.

Whilst the risk of modern slavery in the Group's operations is considered low, we are acutely aware that there may be modern slavery risks in the operations of the third party suppliers that provide services to EBOS to support its business operations including IT companies, construction, cleaners, security, packaging freight carriers (international and domestic) and labour hire. For example, some of these industries may engage unskilled migrant workers and source personnel through labour hire agents. We have implemented controls where possible, including contractual obligations with respect to modern slavery requirements in our main supplier agreements. We will continue to seek opportunities to include controls where possible.

In the reporting period for FY24, through operational assessments, we have sought to consolidate our international freight carriers (air and sea shipments) with a view to having more oversight and the ability to have better alignment in our contractual controls in these arrangements. International freight is relevant for businesses across Healthcare and Animal Care. All intended suppliers have been advised of EBOS' ethical sourcing expectations, including an expectation to comply with EBOS' Supplier Code of Conduct, due diligence measures and a commitment to data sharing and transparency. The Group will work towards finalising these third party arrangements into FY25.

As EBOS continues to invest in its infrastructure, with a commitment to sustainability, we are cognisant of exposure to potential modern slavery risks in our major projects. In FY24, where appropriate, we have sought to include ethical sourcing requirements in our tender process when engaging with third party suppliers across the Group's significant infrastructure projects.

We will continue to consider appropriate mechanisms to monitor these risks in the increasingly complex supply chains of the third parties with whom we deal with and opportunities to include controls where possible.

The Group recognises and continues to monitor potential exposure to modern slavery risk in the context of its own operations.

Our Supply Chains

The diversity within our Group necessarily means that our supply chains are complex. Our Healthcare segment generally comprises goods sourced from global pharmaceutical companies. Whilst in most instances, our contractual arrangements are with an Australian based entity, we are aware that these goods are often sourced from companies and manufacturers based in regions including Europe, the United States, India and Asia. Some of these are considered to be high risk geographies. In addition, the production of garments (PPE) and medical and surgical instruments and consumables has been linked to labour and human rights violations

In our Medical Technology business, as a distributor of specialist medical devices, we engage with specialist suppliers from a number of countries to source products including Germany, the United States, Turkey, Netherlands, the UK and Finland. Some of these countries have been identified as presenting a potentially elevated exposure to modern slavery risk. More broadly, we are conscious that a large proportion of key inputs required for end stage assembly of surgical and medical products are manufactured in high-risk countries such as Malaysia, Pakistan and Thailand. Whilst the focus of our Ethical Sourcing Strategy is on Tier 1 suppliers, as the strategy evolves, we will look to understand more fully and mitigate the risks associated with suppliers down the tiers.

In general, risks of modern slavery in our supply chain are relatively low due to the highly regulated nature of the pharmaceutical and medical supplies industry. However, we have assessed that those goods and services that we procure from certain geographical regions may have an elevated risk of exposure. The goal of EBOS' strategy on ethical sourcing is to engage with suppliers that are aligned with our values.

OUR ACTIONS TO ASSESS AND ADDRESS OUR MODERN SLAVERY RISKS (INCLUDING DUE DILIGENCE AND REMEDIATION)

In FY23 EBOS commenced the roll-out of its formal Ethical Sourcing Strategy as part of the broader ESG Program. As foreshadowed in our FY23 statement, our businesses have continued to work through implementing and embedding these initiatives into their operations through FY24.

The goal of the Ethical Sourcing Strategy is to engage with suppliers and service providers that are aligned with EBOS' broader corporate values, including a respect for worker's rights. Whilst the Ethical Sourcing Strategy has drawn on work done in previous years, the intention is to formalise these activities in a way that is measurable and can be accurately reported on. Importantly, EBOS will also continue to seek to highlight areas where the Group can improve thereby enabling more structured governance, evaluation and disclosure as part of our approach to responsible corporate leadership. Adopting a continuous improvement approach, we will continue to review and adapt the Ethical Sourcing Strategy where appropriate based on learnings as our businesses continue to embed the strategy, including increasing engagement with suppliers.

The Strategy recognises that EBOS' businesses are diverse by the nature of their operations and the products and services. However, there are key common processes in relation to ethical sourcing that each business is expected to embed in their operations. Each business is responsible for implementing the strategy tailored to address the modern slavery and ethical sourcing risks that are most appropriate to it.

The Ethical Sourcing Strategy includes the following initiatives that are common expectations across all EBOS businesses:

Risk Assessment

Recognising that risk is influenced by various factors, including for example, inherent industry risk, geographic risk, whether or not the product is own-brand, each business will be required to determine its parameters and prioritisation of risk for its suppliers based on the most appropriate category of risk depending on the nature of its business and industry.

Each of our businesses have access to external resources to assist in considering risk such as LSEG Risk Intelligence (formerly Refinitiv World Check Risk Intelligence) and Sedex.

Examples of supply chain risk categories assessed by our businesses
Product/service quality risks
Industry risks
Geographic risks
Entity risks including reputation
Exposure related to supplier size

• Due Diligence

Businesses are required to complete due diligence on risk-assessed entities that they engage with. Our businesses have implemented Standard Operating Procedures that reflect the particular business' approach to due diligence.

Our businesses are using tools such as LSEG Risk Intelligence, Sedex and due diligence questionnaires to assess their engagement with existing suppliers (with those suppliers who have been categorised as higher risk taking priority) and in the on-boarding process (where relevant) for new suppliers.

Audits may also be part of the due diligence measures in circumstances primarily where the initial risk assessment or due diligence results indicate an unacceptable level of risk or in relation to businesses with own-brand products.

During FY24, our businesses continued to embed due diligence processes into their operations and actively engage with suppliers to complete such measures. Whilst some of our suppliers have now completed this process through the Sedex platform or the manual due diligence questionnaire, due to the complex and often global nature of some of our supply chains, this continues to be an on-going process both in respect of existing Tier 1 suppliers and new suppliers being onboarded.

Other Controls

These measures include businesses raising awareness within their supplier cohort of EBOS' requirements in relation to compliance with EBOS' Supplier Code of Conduct and Ethical Sourcing Policy and continuing to embed modern slavery requirements into all supplier contracts (where appropriate).

In FY24, we took the opportunity to strengthen our standard contractual controls which we intend, to the extent practical, to embed as contracts are renewed or entered into to ensure compliance with the principles set out in the Group's Supplier Code of Conduct and a commitment from suppliers to engage with the Group's due diligence measures if required.

Reporting

Businesses are required to report bi-annually on factors such as any modern slavery initiatives, any instances of critical non-conformance with suppliers and progress on implementation.

Escalation mechanisms are incorporated into a business' Standard Operating Procedures where the results of a supplier's risk assessment or response to due diligence are of concern and immediate action is required.

• Training

Modern slavery training is included for all relevant employees as part of EBOS' formal Integrity Training program. Employees are required to complete this training annually. The online training is designed to raise awareness of modern slavery and how to identify modern slavery risks.

In addition to the ESG Program, EBOS' governance framework includes policies which are relevant to addressing modern slavery in its operations and supply chains:

- Code of Ethics: sets out a framework of expected behaviours that reflects the Group's values. It covers expectations in relation to the conduct of EBOS people, particularly in relation to acting honestly, with integrity and in accordance with law. The Code is supplemented by detailed policies and procedures addressing various policy areas of direct relevance to the Group's ESG Program. Any material breaches/matters of the Code are to be reported to the Audit and Risk Committee. The Code is provided to all our employees and officers upon commencement of their employment with us, and where appropriate, to our business partners on their appointment with us.
- Whistleblower Protection Policy: willingness to speak up when something is wrong is central to our corporate culture of honesty and integrity. This policy provides a mechanism for raising and appropriately addressing issues if they arise.

EBOS has a number of employment related policies which are relevant to addressing labour standards and clearly articulates its expectations in relation to those standards in its operations. These policies reflect EBOS' commitment to building an engaged, diverse and talented workforce and ensuring responsible and ethical behaviour in all areas of our business.

• Culture and Engagement

EBOS People policies and practices underpin the Group's culture of caring and accountability. An engaged and aligned workforce helps drive performance, so we regularly ask our people for feedback through our confidential Engagement Survey. We have clearly articulated our Diversity & Inclusion policy and programs. Together with our framework of Workplace Policies supporting positive workplace behaviours, these help to deliver on our commitments for Gender Diversity and Reconciliation

If an instance of modern slavery is identified in our supply chain, this will be escalated, and we will address the situation in a timely manner and in line with EBOS's values and standards. Our business have included in their respective Standard Operating Procedures, a process for escalation and remediation in the event that an instance of modern slavery is identified or where there is a critical risk identified as a result of the due diligence. Depending on the nature of the non-conformance and severity of harm (or potential harm), our preference is to work with suppliers to remediate the non-conformance with a view to improving working conditions for workers.

Key People Policies



Workplace Discrimination and Bullying Policy

• Outlines roles and responsibilities and a complaints procedure



Grievance and **Complaints Procedure**

• Includes procedures for making and investigating a grievance or complaint according to the circumstances



Recruitment and Selection Policy

- Outlines the principles and procedures for the attraction of talent and the recruitment and selection of employees
- Designed to ensure that the recruitment process is consistent and offers equal opportunity in all circumstances



Flexible Working Policy

- Covers the requirements under the National Employment Standards in Australia and minimum obligations in New Zealand
- Structured approach to requesting, reviewing and approving flexible work arrangements, including safety requirements



Workplace Gender workplace Gen Equality Policy

- Promotes gender equality (including equal remuneration) and removal of barriers to full and equal participation of women in the workforce (including in relation to family and caring responsibilities)
- Fosters workplace consultation between employers and employees



Diversity and **Inclusion Policy**

- Reflects our vision to create an environment that is safe, inclusive and leverages the potential of our people irrespective of difference
- Diversity and inclusion in the workplace improves our ability to attract, retain, motivate and develop talent



Health and Wellbeing Policy

- Includes Areas of Focus such as providing our 'Be Well from Anywhere' program, access to annual flu vaccinations and providing mental health awareness training for our leaders
- Committed to building a diverse and inclusive culture that is free from bullying and harassment



- Outlines standards of conduct and ethical behaviour, corporate compliance and good corporate governance
- Includes a framework of standards by which the directors, employees and contractors of EBOS and its related companies are expected to conduct their professional lives

MEASURING OUR EFFECTIVENESS

The Group's focus for FY24 has been to progress implementation of the Ethical Sourcing Strategy across the Group and to ensure that all our businesses are on-boarded and provided with the necessary awareness and training to undertake meaningful risk assessments and due diligence of its suppliers to identify risks of modern slavery in their supply chains.

The initial implementation of our Strategy has provided our businesses with a framework within which to identify and prioritise the higher risk suppliers (for example, those identified as Tier 1) and to engage with those suppliers in the first instance.

During the FY24 period, with the exception of our Lyppard and Australian Biotechnologies businesses, all our Australian and New Zealand businesses have now been onboarded, with a significant number of suppliers being screened through the LSEG Risk Intelligence online tool. Some suppliers are also now engaging with EBOS businesses for due diligence purposes via Sedex or where appropriate, the completion of manual due diligence questionnaires. We appreciate that this is an on-going process. We will continue to engage with our suppliers and monitor the responses that are being received during FY25. We expect that as our businesses continue to work with suppliers our ability to report and measure will become more meaningful.

We will also continue to work with our businesses within each segment to review and assess the self assessment reporting requirements put in place as part of the implementation of the strategy to ensure that sufficient information is captured to be able to measure and report on effectiveness of initiatives for a particular business.



CONSULTATION AND COLLABORATION


EBOS operates a number of diverse businesses. We are continuing to engage with the business representatives to communicate expectations, raise awareness and understand how best to embed the measures in a manner that is meaningful and appropriate within the context of the relevant business. For example, for some businesses depending on the number of suppliers, it is more appropriate for all suppliers to complete due diligence measures, while for others, the focus will be on prioritising risk assessments and completing due diligence on those considered to be high risk in the first instance.

As part of the Group's Ethical Sourcing Strategy, all businesses are required to complete a report to support the initiatives set out in the Group's Modern Slavery Statement. The format of the report is standard across all EBOS businesses and includes details of each business' operations, location of Tier 1 suppliers, risk factors considered by the business, due diligence undertaken and any risks of modern slavery identified, together with any remediation steps where relevant.

A monthly cross business Ethical Sourcing Working Group has been set up and is attended by nominated business representatives responsible for the day-to-day management of the ethical sourcing program in that business. This forum provides a valuable opportunity to share learnings, new initiatives, approaches and resources. In addition, the working group provides a forum to engage with third parties to share industry knowledge. For example, in FY24, the working group hosted a session by an external law firm that presented on recent developments, adequacy of due diligence measures and industry insights in relation to modern slavery and human rights.

In FY24, a number of our businesses worked with Sedex to host supplier information sessions to assist our suppliers in understanding how to use and navigate the platform. We will look to host additional joint supplier information sessions with Sedex during the FY25 reporting period. In addition, during the FY 24 reporting period, our EBOS Healthcare business presented on the Group's ESG program to the peak body for the day hospital sector.

We are exploring opportunities to participate more broadly in external forums and will look to actively do so in FY25.



OUR NEXT STEPS

The overarching focus for FY24 was to continue to embed the Ethical Sourcing Strategy into each of our businesses to ensure that across our operations and supply chains, processes are in place to identify, prevent, mitigate and manage the risk of modern slavery. This will remain our focus in the coming year. In particular, we will continue to focus on:


- Supplier due diligence and on-boarding: more actively engage with our suppliers to facilitate participation and completion of due diligence measures.
- External engagement: seek opportunities to actively engage in external forums to continue to build awareness and understanding of modern slavery risks and to share learnings on how these risks are being managed and mitigated.
- Measuring effectiveness: explore mechanisms to measure the effectiveness of initiatives that have been implemented.
- Controls: review our standard contractual clauses to ensure that they continue to reflect EBOS' values and approach to modern slavery.
- Onsite investigation: ensure that our businesses are actively seeking to consider and implement due diligence measures, such as audits, where appropriate and work towards looking beyond Tier 1 suppliers.

Signed on behalf of EBOS Group Limited and the subsidiaries listed in Appendix A by:

EM Cuto

Liz Coutts
Chair of the Board

20 August 2024



APPENDIX A

Entities within EBOS Group

New Zealand

Name	New Zealand Company Number
Clinect NZ Pty Limited	5248181
EBOS Medical Devices NZ Limited	7688556
Endeavour Consumer Health Limited	2336947
Masterpet Corporation Limited	8582
PRNZ Limited	1715066
Pharmacy Retailing NZ Limited	49549
Protec Solutions Limited	892905
W M Bamford & Co Limited	15071

Australia

Name	Australian Company Number
A.C.N. 618 208 969 Pty Ltd	618 208 969
Alchemy Holdings Pty Ltd	604 670 493
Alchemy Sub-Holdings Pty Ltd	604 695 365
Beaphar Pty Ltd	145 508 729
BFCMC Pty Ltd	622 474 855
Blackhawk Premium Pet Care Pty Ltd	150 390 686
Botany Bay Imports Exports Pty Ltd	128 341 980
CAB Medical Pty Ltd	604 292 793
CC Pharmacy Investments Pty Ltd	128 459 030
CC Pharmacy Management Pty Ltd	128 459 049
CC Pharmacy Promotions Pty Ltd	154 871 753
Chemmart Holdings Pty Ltd	614 007 288
Chem Plus Pty Ltd	008 274 557
Cincotta Holding Company Pty Ltd	169 308 070
Clinect Pty Ltd	150 558 473
Collaboration Medical Clinics Investments Pty Ltd	603 715 000
Collaboration Medical Clinics Pty Ltd	622 474 435
Developing People Pty Ltd	115 878 227

Australia continued

Name	Australian Company Number
DoseAid Pty Ltd	129 958 934
*EAHPL Pty Ltd	164 521 617
EBOS Aesthetics Pty Ltd	645 058 840
* EBOS Group Australia Pty Ltd	125 401 247
EBOS Health & Science Pty Ltd	003 274 502
* EBOS Medical Devices Australia Pty Ltd	635 893 720
* EBOS PH Pty Ltd	613 974 253
Endeavour CH Pty Ltd	003 631 669
Fibertech Medical Australia Pty Ltd	157 788 362
* Healthcare Supply Partners Pty Ltd	631884609
Hospharm Pty Ltd	136 875 922
HPS Brands Pty Ltd	167 204 962
HPS Corrections Pty Ltd	159 945 936
HPS Finance Pty Ltd	169 377 986
HPS Holdings Group (AUST) Pty Ltd	158 830 641
HPS Hospitals Pty Ltd	158 418 038
HPS IVF Pty Ltd	156 303 561
HPS Services Pty Ltd	160 438 559
Intellipharm Pty Ltd	001 235 374
Klinic Solutions Pty Ltd	130 793 261
Lite Living Pty Ltd	166 526 370
LMT Surgical Pty Ltd	092 902 111
* Lyppard Australia Pty Ltd	007 008 906
* Masterpet Australia Pty Limited	000 333 353
Masterpet Logistics Pty Ltd	146 338 418
MD Solutions Australasia Pty Ltd	099 040 874
MD Scopes Pty Ltd	113 630 381
Mega Save Management Pty Ltd	128 266 437
National Surgical Pty Ltd	078 902 217
Nexus Australasia Pty Limited	115 828 941
PBA Finance No. 1 Pty Ltd	624 432 471

Australia continued

Name	Australian Company Number
PBA Finance No. 2 Pty Ltd	168 983 597
PBA Wholesale Pty Ltd	157 770 244
* Pet Care Distributors Pty Ltd	125 265 769
* Pet Care Holdings Australia Pty Ltd	000 060 364
Pet Care Wholesalers Pty Ltd	637 762 077
Pets International Pty Ltd	002 960 330
Pharmacy Brands Australia Pty Ltd	109 700 263
Qpharma Pty Ltd (previously Aristopet)	145 418 882
Richard Thomson Pty Limited	115 059 179
Sentry Medical Pty Ltd	003 634 991
* Symbion Pty Ltd	000 875 034
Surgical and Medical Supplies	007 707 128
* Terry White Group Pty Ltd	136 808 243
Tony Ferguson Weight Management Pty Ltd	166 526 665
* TW&CM Pty Ltd	136 833 620
TWC IP Pty Ltd	136 833 611
Ventura Health Pty Ltd	169 307 975
VIM Health Pty Ltd	166 525 659
VIM Health IP Pty Ltd	166 527 555
Vitapet Corporation Pty Limited	079 725 143
W & W Management Services Pty Ltd	606 748 047
Warner And Webster Pty Limited	004 518 156
You Save Management Pty Ltd	125 763 680
* ZAP Services Pty Ltd	132 014 174
* ZHHA Pty Ltd	131 957 269

LifeHealthcare

Name	Australian Company Number
* Pacific Health Supplies TopCo1 Pty Limited	624 030 897
* Pacific Health Supplies TopCo Pty Limited	624 032 051
* Pacific Health Supplies Mezzco Pty Limited	624 032 908
* Pacific Health Supplies Holdco Pty Limited	624 033 450
* Pacific Health Supplies Bidco Pty Limited	624 033 889
* LifeHealthcare Group Pty Limited	166 525 186
* LifeHealthcare Finance Pty Limited	166 526 941
* LifeHealthcare Pty Limited	130 225 599
* LifeHealthcare Distribution Pty Ltd	117 449 911

^{*}Reporting entities as at 30 June 2024



ebosgroup.com

